Annotation Detail

Information
Associated Genes
MTTP
Associated Variants
MTTP MUTATION
MTTP MUTATION
Associated Disease
Myeloid Leukemia, Chronic
Source Database
DisGeNET
Description
Despite the clinical efficacy achieved with frontline therapies for BCR-ABL-positive disease, such as imatinib and second-generation ABL inhibitors like nilotinib or dasatinib that were originally designed to override insensitivity to imatinib, drug resistance still remains a challenge, especially for patients with advanced-stage chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Pubmed
25331939
Section of the abstract supporting the evidence
ALL_TEXT_1/3
Number of the section of the abstract supporting the evidence
1
Number of the sentence supporting the evidence
1
Original source reporting the Gene Disease association
BeFree
DisGENET score for the Gene Disease association
0.0553741419043819
Drugs